- 现金
- 222032 元
- 精华
- 285
- 帖子
- 67620
- 注册时间
- 2001-11-10
- 最后登录
- 2023-5-7
|
18楼
发表于 2002-8-24 21:27
加拿大的一项研究显示, 对Adefovir Dipivoxil进行了60周乙肝治疗用药结果发现并不会产生抗药(变异)现象.
此外, 服用ADV应该在有知识的医生指导下, 每个月验血(具体有几项必须检查项目, 一时记不起来, 下次去FDA网站时再记下来).
原文简摘:
AUGUST 2002 VIRAL HEPATITIS B- Resistance Surveillance in Chronic Hepatitis B Patients Treated with Adefovir Dipivoxil for up to 60 Weeks
H. Yang (1), C. E. Westland (1), W. E. Delaney IV (1), E. J. Heathcote (2), V. Ho (1), J. Fry (1) , C. Brosgart (1), C. S. Gibbs (1), M. D. Miller (1), S. Xiong (1)
(1) Gilead Sciences Inc., Foster City, CA; (2)Toronto Western Hospital, Toronto, Ontario, Canada.
Current therapies for chronic hepatitis B virus (HBV) infection do not provide adequate long-term control of viral replication in the majority of patients. Monotherapy with nucleoside analogs, such as lamivudine and famciclovir, is effective for short periods but results in the emergence of drug-resistant HBV in a substantial number of patients within 1 year of therapy. Adefovir dipivoxil (ADV) has demonstrated clinical activity against wild-type and lamivudine-resistant HBV, but it is unclear whether resistance mutations will emerge after long-term therapy with this drug. To determine whether extended treatment with ADV led to the emergence of drug-resistant populations of HBV, we analyzed virus isolated from patients currently enrolled in a long-term open-label study. The reverse transcriptase domain of HBV polymerase was amplified and sequenced from patients that had received a cumulative exposure of up to 60 weeks of ADV. During our analyses, several previously unreported amino acid substitutions were observed in the reverse transcriptase domain of HBV. Importantly, none of the observed mutations occurred in more than 1 patient, nor were they associated with an adefovir-resistant phenotype in vitro. Furthermore, none of the patients from whom these mutant viruses were isolated had evidence of virologic rebound. In conclusion, these results, although based on a limited number of patients, suggest that treatment with ADV does not lead to the emergence of resistant virus after up to 60 weeks of therapy. (Hepatology;36,464-473,2002.)
[B](仅作为HBVHBV.COM网友内部交流, 指正)[/B]
|
|